HBV disease: HBsAg carrier and occult B infection reactivation in haematological setting

Digestive and Liver Disease

Volumn 43, Issue SUPPL. 1, 2011, Pages

  Marinone, Carlo ^a   Mestriner, Monica ^a  

^a MOLINETTE HOSPITAL   (Italy)

Author keywords

High risk reactivation; Targeted prophylaxis; Universal prophylaxis

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ALEMTUZUMAB; ANTHRACYCLINE; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; BLEOMYCIN; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DOXORUBICIN; ENTECAVIR; FLUDARABINE; HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HYDROXYUREA; LAMIVUDINE; MELPHALAN; MERCAPTOPURINE; METHOTREXATE; MYCOPHENOLIC ACID; RITUXIMAB; TACROLIMUS; TENOFOVIR; TIOGUANINE; VINCRISTINE; VIRUS DNA;

ADD ON THERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOTRANSPLANTATION; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CHEMOPROPHYLAXIS; DRUG EFFECT; DRUG EFFICACY; HEMATOLOGIC MALIGNANCY; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HIGH RISK PATIENT; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INFECTION RISK; LYMPHOMA; MIXED INFECTION; MYELOABLATIVE CONDITIONING; NONHODGKIN LYMPHOMA; PATIENT IDENTIFICATION; PREVALENCE; PRIORITY JOURNAL; RISK REDUCTION; VIRUS CARRIER; VIRUS LOAD; VIRUS REACTIVATION;

ANTIBIOTIC PROPHYLAXIS; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; CARRIER STATE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; IMMUNOSUPPRESSION; LEUKEMIA; LYMPHOMA; VIRUS ACTIVATION;

EID: 78650671856     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1590-8658(10)60692-5     Document Type: Article

References (50)

1. Firpi RJ, Nelson DR Management of viral hepatitis in hematologic malignancies. Blood Rev 2008, 22:117-126.
2. Liang R How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stemcell transplantation. Blood 2009, 13:3147-3153.
3. Dienstag JL Hepatitis B virus infection. N Engl J Med 2008, 359:1486-1500.
4. Weinbaum CM, Williams I, Mast EE, et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 2008, 57:1-20.
5. Mele A, Tosti ME, Mariano A, et al. Acute hepatitis B 14 years after the implementation of universal vaccination in Italy: areas of improvement and emerging challenges. Cin Infect Dis 2008, 46:868-875.
6. Liang R, Lok ASF, Lai CL, et al. Hepatitis B infection in patients with lymphomas. Hemat Oncol 1990, 8:261-270.
7. Marcucci F, Mele A, Spada E, et al. High prevalence of hepatitis B virus infection in B-cell non-Hodgkin's lymphoma. Haematologica 2006, 91:554-557.
8. Chen MH, Hsiao LT, Chiou TJ, et al. High prevalence of occult hepatitis B infection in patients with B-cell non-Hodgkin's lymphoma. Ann Hematol 2008, 87:475-480.
9. Lok ASF Natural history and control of perinatally acquired hepatitis B virus infection. Dig Dis 1992, 10:46-52.
10. Raimondo G, Pollicina T, Cacciola I, et al. Occult hepatitis B virus infection. J Hepatol 2007, 46:160-170.
11. Chemin I, Trepo C Clinical impact of occult HBV infections. J Clin Virol 2005, 34:S15-S21.
12. Shih CM, Lo SJ, Miyamura T, et al. Suppression of hepatitis B virus expression and replication by hepatitis C virus core protein in HuH-7 cells. J Virol 1993, 67:5823-5832.
13. Schuttler CG, Fiedler N, Schmidt K, et al. Suppression of hepatitis B virus enhancer 1 and 2 by hepatitis C virus core protein. J Hepatol 2002, 37:855-862.
14. Villa E, Grottola A, Buttafoco P, et al. Evidence of hepatitis B virus infection in patients with chronic hepatitis C with and without serological markers of hepatitis B. Dig Dis Sci 1995, 40:8-13.
15. Torbenson M, Thomas DL Occult hepatitis B. Lancet Infect Dis 2002, 2:479-486.
16. Galbraith RM, Eddleston AL, Williams R Fulminant hepatic failure in leukaemia and choricarcinoma related to withdrawal of cytotoxic drug therapy. Lancet 1975, 2:528-530.
17. Xunrong L, Yan AW, Liang R, et al. Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy - pathogenesis and management. Rev Med Virol 2001, 11:287-299.
18. Nakamura Y, Motokura T, Fujita A, et al. Severe hepatitis related to chemotherapy in hepatitis B virus carrier with hematologic malignancies. Survey in Japan 1987-1991. Cancer 1996, 78:2210-2215.
19. Markowitz JS, Martin P, Conrad AJ, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998, 28:585-589.
20. Hui CK, Cheung WW, Zhang HY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006, 131:59-68.
21. Yeo W, Zee B, Zhong S, et al. Comprehensive analysis of risk factors associating with hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 2004, 90:1306-1311.
22. Lau GK, Leung YH, Fong DY, et al. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for the HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood 2002, 99:2324-2330.
23. Yeo W, Chan TC, Leung NW, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009, 27:605-611.
24. Metzler F, Mederacke I, Manns MP, et al. Rituximab leads to reactivation of hepatitis B in individual with resolved infection. Hepatology 2008, 48(Suppl 4):685A. abstract 848.
25. Aksoy S, Harputluoglu H, Kilckap S, et al. Rituximab related viral infection in lymphoma patients. Leuk Lymphoma 2007, 48:1307-1312.
26. Armitage JO How I treat patients with diffuse large B-cell lymphoma. Blood 2007, 110:20-36.
27. Iannito E, Minardi V, Calvaruso G, et al. Hepatitis B virus reactivation and alemtuzumab. Eur J Haematol 2005, 74:254-258.
28. Frank DA, Mahajan S, Ritz J Fludarabine induced immunosuppression is associated with inhibition of STAT1 signaling. Nat Med 1999, 4:444-447.
29. Lau GKK Hepatitis B reactivation after chemotherapy: two decades of clinical research. Hepatol Int 2008, 2:152-162.
30. Yeo W, Chan PK, Zhong S, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000, 63:299-307.
31. Lok AS, Liang RH, Chiu EK, et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991, 100:182-188.
32. Onozawa M, Hashino S, Izumiyama K, et al. Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation 2005, 79:616-619.
33. Sera T, Hiasa Y, Michitaka K, et al. Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab. Intern Med 2006, 45:721-724.
34. Perceau G, Diris N, Estines O, et al. Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma. Br J Dermatol 2006, 155:1053-1056.
35. Targhetta C, Cabras MG, Mamusa AM, et al. Hepatitis B virus related liver disease in isolated anti-hepatitis B-core positive lymphoma patients receiving chemo- or chemo-immune therapy. Haematologica 2008, 93:951-952.
36. Koo YX, Tan SW, Tan IB, et al. Hepatitis B virus reactivation in a patient with resolved hepatitis B virus infection receiving maintenance rituximab for malignant B-cell lymphoma. Ann Intern Med 2005, 150:655-656.
37. Ziakas PD, Karsaliakos P, Mylonakis E Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance. Haematologica 2009, 4:998-1005.
38. Marzano A, Angelucci E, Andreone P, et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis 2007, 39:397-408.
39. Loomba R, Rowley A, Wesley R, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008, 148:519-528.
40. Firpi R, Nelson DR Viral hepatis manifestation and management strategy. Haematol Am Soc Haematol Educ Program 2006, 275-380.
41. Lau GKK, Yiu HH, Fong DY, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003, 125:1742-1749.
42. Hsu C, Hsiung CA, Su IJ, et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B virus reactivation in non-Hodgkin's lymphoma: a randomized trial. Hepatology 2008, 47:844-853.
43. Pelizzari AM, Motta M, Cariani E, et al. Frequency of hepatitis B virus mutant in asymptomatic hepatitis B virus carriers receiving prophylactic lamivudine during chemotherapy for hematologic malignancies. Hematol J 2004, 5:325-328.
44. Barclay S, Pol S, Mutimer D, et al. The management of chronic hepatitis B in the immunocompromised patient: recommendations from a single topic meeting. J Clin Virol 2008, 42:104-115.
45. Mindikoglu AL, Regev A, Schoff ER Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and its prevention. Clin Gastroenterol Hepatol 2006, 4:1076-1081.
46. Lalazar G, Rund D, Shouval D Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 2007, 136:699-712.
47. Moses SE, Lim ZY, Sudhanva, et al. Lamivudine prophylaxis and treatment of hepatitis B virus-exposed recipients receiving reduced intensity conditioning hematopoietic stem cell transplants with alemtuzumab. J Med Virol 2006, 78:1560-1563.
48. Giaccone LO, Festuccia M, Marengo A, et al. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2010, 16:809-817.
49. Strasser SI, McDonald GB Hepatitis viruses and hematopoietic cell transplantation: a guide to patient and donor management. Blood 1999, 93:1127-1136.
50. Loomba R, Liang TJ Novel approaches to new therapies for hepatitis B virus infection. Antivir Ther 2006, 11:1-15.